Clinical trial
Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.
NCT05128630
Study timeline
Study start (actual)2021-10-28Date precision: day
Registry last updated2023-09-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
NSCLC, Stage IIIunresolved
Interventions
DurvalumabDRUG · verified · RxNorm: durvalumab
Sponsors & collaborators
Fondazione IRCCS Policlinico San Matteo di Pavialead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05128630 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.